ArticlePloS one2025
Viral kinetics among persons living with HIV (PLWH) on Dolutegravir-based antiretroviral Regimen: A retrospective and prospective analysis from selected HIV clinics in Ghana.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- One- and Two-Year Outcomes of Switching to a Dolutegravir-Based ART Regimen: An Observational Emulation of Sequential Target Trials.Open forum infectious diseases · 2026Article
- Cohort profile: the pharmacogenomics and pharmacokinetics study in Ghanaian HIV patients (GenoPharm-GH).BMC genomic data · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDolutegravir (DTG)-based antiretroviral therapy has demonstrated superior efficacy, tolerability, and durability when compared to other HIV treatment regimens. However, monitoring viral kinetics is critical for determining treatment efficacy and making sound judgments. The purpose of this study was to assess viral kinetics in people living with HIV (PLWH) on DTG-based ART and identify characteristics related to virologic response in the Cape Coast Metropolis, Ghana.
methodsAmong people living with HIV (PLWH) attending HIV clinics between January 2020 and December 2023, a prospective and retrospective analysis of viral kinetics and clinical data were carried out. Data on viral loads, clinical laboratory results, ART regimen, and sociodemographic data were gathered. Viral loads analysis was undertaken using the COBAS AmpliPrep/COBAS TaqMan HIV-1 test, v2.0. Univariate and multivariate analyses were carried out to assess the variables related to virologic response.
resultsComplete data was obtained for a total of 902 PLWH in this study. The average age was 45 ± 15.30 years, and 72.62% were female. The majority, 89.02% (835/902), had been on the DTG+3TC+TDF regimen. Over 60% had undetectable viral loads (<50 copies/mL). Univariate analysis shows a significant relationship between gender and virologic response, with females having a lower likelihood of virologic failure (OR: 0.60, 95% CI: 0.39-0.93, p-value = 0.024). In multivariate analysis, the duration of ART had various relationships with virologic response, with the odds ratio for two years reaching near significance (OR: 1.88, 95% CI: 0.98-3.59, p = 0.057). PLWH with viral loads >1000 copies/mL were 11.20% (101/902) while viral suppression, which was at detectable limits (>50 - ≤ 1000 cp/mL), was 13.08% (118/902) showing high rates of viral suppression.
conclusionThe presence of virologic failures was of concern despite the high rates of viral suppression that DTG-based ART demonstrated. Undetectable viral suppression was higher than detectable viral suppression. Regular monitoring of viral kinetics, adherence, and comorbidities is essential to meeting the United Nations program on HIV/AIDS (UNAIDS) 95-95-95 targets and providing efficient therapeutic approaches for PLWH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.